Skip to main content

Access to Treatment of Hepatitis C in Prison Inmates

Digestive Diseases and Sciences volume 54, Article number: 1325 (2009) Cite this article

Abstract

We conducted a prospective study to investigate access to treatment in hepatitis C in 268 prisoners. Hepatitis C positivity had been known for 182 prisoners previously and 19 reported previous attempts to treat (10%). In comparison, during our study, 86/268 prisoners (32%) started therapy (P < 0.0001). They represented 41% of 211 prisoners with a positive viral load. In the genotype 2 or 3 group, 46 prisoners (50%) started therapy versus 40 prisoners (33%) with other genotypes (P = 0.01). This difference was due to prisoners waiting for liver biopsy. On an intention to treat basis, 45 prisoners (52%) achieved sustained virological response 6 months after the end of therapy. We conclude that a stay in prison is an effective opportunity to treat a group of hepatitis C patients which otherwise have very limited access to therapy.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. EASL International Consensus Conference on hepatitis C. J Hepatol. 1999;31(suppl 1):3–8. doi:10.1016/S0168-8278(99)80367-5.

    Google Scholar 

  2. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562. doi:10.1056/NEJM199908193410802.

    PubMed  Article  CAS  Google Scholar 

  3. Remy AJ. Hepatitis C in prison settings: screening and therapy are improving. Presse Med. 2006;35:1249–1254. doi:10.1016/S0755-4982(06)74797-2.

    PubMed  Article  Google Scholar 

  4. Claudon-Charpentier A, Hoibian M, Glasser P, Lalanne H, Pasquali JL. Drug addicted inmates of the Elsau prison, Strasbourg, France. Rev Med Interne. 2000;21:505–509. doi:10.1016/S0248-8663(00)89225-5.

    PubMed  CAS  Article  Google Scholar 

  5. Holsen DS, Harthug S, Myrmel H. Prevalence of antibodies to hepatitis C virus and association with intravenous drug abuse and tattooing in a national prison in Norway. Eur J Clin Microbiol Infect Dis. 1993;12:673–676. doi:10.1007/BF02009378.

    PubMed  Article  CAS  Google Scholar 

  6. Allwright S, Bradley F, Long J, Barry J, Thornton L, Parry JV. Prevalence of antibodies to hepatitis B, hepatitis C and HIV and risk factors in Irish prisoners: result of a national cross sectional survey. BMJ.. 2000;321:78–82. doi:10.1136/bmj.321.7253.78.

    PubMed  Article  CAS  Google Scholar 

  7. Gore SM, Bird AG, Cameron SO, Hutchinson SJ, Burns SM, Goldberg DJ. Prevalence of hepatitis C in prison. Q J Med. 1999;92:25–32.

    CAS  Google Scholar 

  8. Hedouin V, Gosset D. Hepatitis C virus infection in a prison population. Gastroenterol Clin Biol. 1998;22:55–58.

    PubMed  CAS  Google Scholar 

  9. Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM. Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut. 2003;52:1500–1504. doi:10.1136/gut.52.10.1500.

    PubMed  Article  CAS  Google Scholar 

  10. Morrison DS, Gilchrist G. Prison admission health screening as a measure of health needs. Health Bull (Edinb). 2001;59:114–119.

    CAS  Google Scholar 

  11. Christensen PB, Krarup HB, Niesters HGM, Norder H, Georgsen J. Prevalence and incidence of bloodborne viruses among Danish prisoners. Eur J Epidemiol. 2000;16:1043–1049. doi:10.1023/A:1010833917242.

    PubMed  Article  CAS  Google Scholar 

  12. Fox RK, Currie SL, Evans J, et al. Hepatitis C virus infection among prisoners in the California state correctional system. Clin Infect Dis. 2005;41:177–186. doi:10.1086/430913.

    PubMed  Article  Google Scholar 

  13. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003;138:187–190.

    PubMed  Google Scholar 

  14. Sterling RK, Hofmann CM, Luketic VA, et al. Treatment of chronic hepatitis C virus in the Virginia department of corrections: can compliance overcome racial differences to response? Am J Gastroenterol. 2004;99:866–872. doi:10.1111/j.1572-0241.2004.30310.x.

    PubMed  Article  Google Scholar 

  15. Blanchet E, Defossez G, Verneau A, Ingrand I, Silvain C, Beauchant M. Epidemiology and management of care of hepatitis C infection in the Poitou-Charentes region in 1997 and 2000. Gastroenterol Clin Biol. 2003;27:1026–1030.

    PubMed  Google Scholar 

  16. Hatem C, Minello A, Bresson-Hadni S, et al. Is the management of hepatitis C patients appropriate? A population-based study. Aliment Pharmacol Ther. 2005;21:1007–1015. doi:10.1111/j.1365-2036.2005.02393.x.

    PubMed  Article  CAS  Google Scholar 

  17. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136:288–292.

    PubMed  CAS  Google Scholar 

  18. Narasimhan G, Sargios TN, Kalakuntla R, et al. Treatment rates in patients with chronic hepatitis C after liver biopsy. J Viral Hepat. 2006;13:783–786. doi:10.1111/j.1365-2893.2006.00763.x.

    PubMed  Article  CAS  Google Scholar 

  19. Shaheen AAM, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology. 2007;46:912–921. doi:10.1002/hep.21835.

    PubMed  Article  Google Scholar 

  20. Bini EJ, Bräu N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol. 2005;100:1772–1779. doi:10.1111/j.1572-0241.2005.41860.x.

    PubMed  Article  Google Scholar 

  21. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kent Kwoh C. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385–389. doi:10.1136/gut.2006.099150.

    PubMed  Article  Google Scholar 

  22. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. doi:10.1056/NEJMoa020047.

    PubMed  Article  CAS  Google Scholar 

  23. Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side-effects. Hepatology. 2007;46:991–998. doi:10.1002/hep.21791.

    PubMed  Article  CAS  Google Scholar 

  24. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998;28:805–809. doi:10.1002/hep.510280330.

    PubMed  Article  CAS  Google Scholar 

  25. McGovern BH, Wurcel A, Kim AY, et al. Acute hepatitis C virus infection in incarcerated injection drug users. Clin Infect Dis. 2006;42:1663–1670. doi:10.1086/504327.

    PubMed  Article  Google Scholar 

Download references

Acknowledgments

The authors would like to thank the nursing, GP, and psychiatric teams of Schrassig prison infirmary, Luxembourg. Without their infallible commitment, this study in particular, and taking care of prisoners with hepatitis C in general, would not have been possible. Special thanks to Professor Christine SILVAIN from the Hepatogastroenterology Unit of the University Hospital in Poitiers, France, for her invaluable help with the design of the study and the manuscript.

Author information

Affiliations

  1. Hepatogastroenterology, Service d’Hépato-Gastroentérologie, Centre Hospitalier de Luxembourg, 4, rue Barblé, Luxembourg-City, 1210, Luxembourg

    Paul Strock

  2. Microbiology, Laboratoire National de Santé, Luxembourg-City, Luxembourg

    Joël Mossong

  3. Retrovirology Laboratory, Centre Hospitalier de Luxembourg, Luxembourg-City, Luxembourg

    Karine Hawotte

  4. Infectious Diseases, Centre Hospitalier de Luxembourg, Luxembourg-City, Luxembourg

    Vic Arendt

Authors
  1. Paul Strock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joël Mossong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karine Hawotte
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vic Arendt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul Strock.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Strock, P., Mossong, J., Hawotte, K. et al. Access to Treatment of Hepatitis C in Prison Inmates. Dig Dis Sci 54, 1325 (2009). https://doi.org/10.1007/s10620-008-0483-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10620-008-0483-8

Keywords

  • Hepatitis C
  • Prison
  • Therapy
  • Epidemiology